Denali Therapeutics Inc. is a biotechnology company that discovers, develops, and delivers biotherapeutics for serious diseases, focusing on overcoming the blood-brain barrier to treat central nervous system conditions. The company utilizes its proprietary TransportVehicle technology to enable the delivery of large molecules, including enzymes, oligonucleotides, and antibodies, to the brain and other tissues. Its therapeutic portfolio is organized into three franchises: Enzyme TV for lysosomal storage diseases, Oligonucleotide TV for neurodegenerative conditions, and Antibody TV for various indications. Key product candidates include tividenofusp alfa for mucopolysaccharidosis II, DNL126 for mucopolysaccharidosis IIIA, DNL593 for frontotemporal dementia, DNL628 for Alzheimer’s disease, and DNL952 for Pompe disease. The company targets rare and common diseases such as Hunter syndrome, Sanfilippo syndrome, Alzheimer’s disease, and Parkinson’s disease. Denali Therapeutics maintains a collaboration with Takeda Pharmaceutical Company Limited for the development and commercialization of TAK-594/DNL593. The company commercializes its approved products in key markets, leveraging its established commercial readiness and patient support services.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage denalitherapeutics.com
Sector Healthcare IR page investors.denalitherapeutics.com
Tags
blood-brain barrier, lysosomal storage diseases, neurodegenerative diseases, enzyme replacement therapy, antibody delivery, oligonucleotide delivery, alzheimer's disease, parkinson's disease, pompe disease, hunter syndrome, sanfilippo syndrome, frontotemporal dementia, TransportVehicle, Enzyme TV, Oligonucleotide TV, Antibody TV, tividenofusp alfa, DNL310, DNL126, DNL593, DNL628, DNL952, DNL921, TAK-594, BIIB122, Takeda
Press page —

Metrics

Valuation  
Market cap $ 3.313B
Market cap (USD) $ 3.313B
P/E -11.95
PEG —
P/BV 3.58
P/S 10.02
P/OCF -7.46
P/FCF -7.41
Dividend yield —
Turnover / mcap —
Returns  
ROE -45.7%
ROI -63.0%
ROIC -51.2%
Profit margin —
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 34
Quality score -52.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Revenue 0 0 330.531M 105.065M 48.657M 335.561M 26.678M 129.16M 0
Net profit -512.54M -422.773M -145.224M -325.991M -290.581M 71.136M -197.614M -36.24M -88.185M
Free cash flow -422.102M -363.606M -370.93M -262.549M -219.889M 413.057M -169.495M 46.723M -79.51M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017
Share price 16.51 20.38 21.46 27.81 44.6 83.76 17.42 20.66 15.64
Price performance 12m -0.19 -0.05 -0.23 -0.38 -0.47 3.81 -0.16 0.32 —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — — 8.59M — — — — 0.00
Lease liabilities (USD) — — — 72.6M 68.9M 64M 60.4M 52.2M 54.3M 42.3M
Cash and deposits (USD) 39.9M 218M 77.1M 79.4M 507M 293M 218M 127M 175M 205M
Intangible assets (USD) — — — — — — — — — 0.00
Right-of-use assets (USD) — — — 33.9M 32.6M 30.7M 30.4M 26M 22.9M 19M
Cash flow detail
Operating cash flow (USD) -72.4M -76.6M 50.1M -152M 416M -211M -245M -358M -348M -413M
Purchases of property, plant and equipment (USD) 6.13M 2.88M -3.39M -17.9M -3.1M -8.5M -17.8M -12.9M -15.9M -9.5M
Change in payables (cash effect) (USD) 161,000 207,000 -526,000 1.03M -1.62M 3.71M 2.27M 2.43M 1.44M -7.52M
Income taxes paid (cash effect) (USD) — — — — 0.00 -210,000 -47,000 -3,000 0.00 -46,000
Share-based compensation (USD) 2.95M 4.41M 18.8M 38.4M 50.4M 85.2M 99.8M 108M 103M 99.6M
Free cash flow (OCF - PPE - intangibles) (USD) -78.5M -79.5M 46.7M -169M 413M -220M -263M -371M -364M -422M
Income detail
Research and development expense (USD) 75.7M 74.5M 143M 193M 213M 265M 359M 424M 396M 419M
↳ 5y CAGR +79.0% +28.5% +37.0% +24.2% +15.4% +14.5%
Total comprehensive income (USD) -87M -88.2M -36.5M -197M 70.5M -293M -330M -138M -421M -514M
Comprehensive income to owners (USD) -87M -88.2M -36.5M -197M 70.5M -293M -330M -138M -421M -514M
Reported Mar 19, 2018 Mar 19, 2018 Mar 12, 2019 Feb 27, 2020 Feb 27, 2023 Feb 27, 2023 Feb 27, 2023 Feb 28, 2024 Feb 27, 2025 Aug 6, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

•AVLAYAH® (tividenofusp alfa-eknm) net product revenue accelerated to $17.8 million in its second full commercial quarter

•Continued growth expectations drive Q4 2026 net product revenue guidance of $30.0 million to $32.0 million

•AVLAYAH recognized as the “Best Biotechnology Product” of 2026 by The Galien Foundation

•Zafinofusp alfa advancing as Denali’s second potential product, with BLA submission on track for 2027 seeking accelerated approval for Sanfilippo syndrome type A (MPS IIIA)

•Five TransportVehicle™ (TV) programs expected to generate data in 2027: zafinofusp alfa (ETV:SGSH), DNL593 (PTV:PGRN), DNL628 (OTV:MAPT), DNL921 (ATV:Abeta) and DNL952 (ETV:GAA)

•Q3 2026 net income of $70.1 million included a one-time $194.0 million net gain on the sale of a Priority Review Voucher, bringing cash, cash equivalents and marketable securities to $1.0 billion

•Conference call and webcast today at 4:30 p.m. ET

SOUTH SAN FRANCISCO, Calif. – November 3, 2026 – Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the third quarter ended September 30, 2026, and provided business highlights.

October 30, 2026

PDF Version

  • First FDA-approved biologic specifically designed to cross blood-brain barrier wins award dedicated to exceptional scientific leadership and transformational impact on patient care

  • First new FDA-approved treatment option in nearly 20 years for families living with Hunter syndrome, a rare neurodegenerative disorder

  • Denali’s brain delivery technology establishes foundation for potential therapies across wide range of diseases that impact the brain, including Alzheimer’s disease

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that AVLAYAH® (tividenofusp alfa-eknm) has been recognized as the “Best Biotechnology Product” of 2026 by The Galien Foundation. AVLAYAH is the first biologic approved by the U.S. Food and Drug Administration (FDA) that is specifically designed to cross the blood-brain barrier and reach the whole body, including the brain. AVLAYAH is an enzyme replacement therapy that received FDA accelerated approval in March 2026 for the treatment of neurologic manifestations of a rare neurodegenerative disease called Hunter syndrome (mucopolysaccharidosis type II, or MPS II) when initiated in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory study.

The Galien Foundation, which fosters and recognizes excellence in scientific innovation that improves the state of human health, presented the 2026 Prix Galien USA “Best Biotechnology Product” award to Denali Therapeutics during a ceremony last night at the American Museum of Natural History in New York City. Prix Galien USA Awards are among the highest honors in the global biopharmaceutical industry, acknowledging the most impactful treatments approved by the FDA within the last five years. Prix Galien winners are selected by committees of the top leaders in science and medicine.

“We are honored to receive the Best Biotechnology Product Award for AVLAYAH, which is a culmination of years of pioneering research to solve the challenge of delivering biologics across the blood-brain barrier with our TransportVehicle technology,” said Ryan Watts, Ph.D., co-founder and Chief Executive Officer of Denali Therapeutics. “This recognition also belongs to the Hunter syndrome community and the families, advocates and clinicians whose determination and commitment made AVLAYAH possible. An FDA-approved medicine that reaches the brain offers transformative possibilities for this community, and it is proof that we can bring the power of biologic medicines to the brain for rare genetic diseases and common neurodegenerative disorders that affect millions of people worldwide.”

Denali’s proprietary TransportVehicle™ technology binds to the transferrin receptor (TfR) and is designed to deliver enzymes, antibodies and oligonucleotides to the whole body, including the brain, through receptor-mediated transcytosis. AVLAYAH is the first and only FDA-approved TfR-enabled medicine engineered to specifically cross the blood-brain barrier.

Denali Therapeutics is advancing a growing portfolio of TransportVehicle-enabled therapeutic candidates across all stages of development, including zafinofusp alfa, an investigational enzyme replacement therapy for the treatment of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A), and two investigational medicines for Alzheimer’s disease (AD) that target the two defining pathologies of the disease. DNL628 (OTV:MAPT) is an Oligonucleotide TransportVehicle-enabled antisense oligonucleotide designed for systemic delivery across the blood-brain barrier to reduce tau by targeting the MAPT gene for the treatment of AD. DNL921 (ATV:Abeta) is an Antibody TransportVehicle-enabled antibody designed for systemic delivery across the blood-brain barrier to target amyloid plaques in AD.

About Hunter Syndrome (MPS II)

Hunter syndrome, also known as MPS II, is a rare genetic lysosomal storage disorder that primarily affects boys and impacts approximately 500 individuals in the United States and 2,000 individuals worldwide. The disease is caused by mutations in the iduronate 2-sulfatase (IDS) gene that results in a deficiency of the IDS enzyme, which is responsible for breaking down glycosaminoglycans (GAGs) such as heparan sulfate and dermatan sulfate. The accumulation of GAGs leads to progressive damage in multiple organs and tissues, including the brain. Symptoms of Hunter syndrome include developmental delays, cognitive decline, behavioral abnormalities and physical complications such as joint stiffness, hearing loss and organ dysfunction.

About AVLAYAH® (tividenofusp alfa-eknm)

AVLAYAH (tividenofusp alfa-eknm) is an intravenous enzyme replacement therapy composed of the iduronate 2-sulfatase (IDS) enzyme fused to Denali’s proprietary TransportVehicle™ (TV) platform. The Fc component of AVLAYAH binds to the apical domain of the transferrin receptor (TfR) and delivers IDS to peripheral tissues and to the central nervous system through receptor-mediated transcytosis across the blood-brain barrier. AVLAYAH is internalized via binding to the mannose-6-phosphate receptor on the cell surface and transported into lysosomes where it is thought to exert enzymatic activity and reduce accumulated glycosaminoglycans (GAGs). In addition, since TfR is ubiquitously expressed, it is expected that the interaction of AVLAYAH and TfR will contribute to its uptake into cells in the brain and peripheral tissues. In addition to Rare Pediatric Disease Designation and Breakthrough Therapy Designation, the U.S. Food and Drug Administration granted Fast Track and Orphan Drug designations to AVLAYAH for the treatment of MPS II.

The European Medicines Agency has granted Priority Medicines designation to tividenofusp alfa. AVLAYAH is not approved by health authorities outside of the U.S.

AVLAYAH U.S. Indication

AVLAYAH is approved for the treatment of neurologic symptoms in pediatric patients weighing at least 5 kg with Hunter syndrome prior to advanced neurologic disease. This approval is based on a reduction of heparan sulfate (HS) in the cerebrospinal fluid (CSF) surrounding the brain and spinal cord. Studies are ongoing to confirm how well it works in improving clinical symptoms.

Limitations of Use

AVLAYAH is not recommended for use in combination with other enzyme replacement therapies.

Important Safety Information

AVLAYAH may cause serious side effects, including:

**Hypersensitivity Reactions including Anaphylaxis.**Life-threatening allergic reactions occurred both early in treatment and after many doses over time, including:

  • Fast heartbeat

  • Dizziness or fainting

  • Wheezing

  • Vomiting

  • Hives

  • Swelling of the lips and tongue

Notify your healthcare provider immediately if these symptoms occur. If a serious allergic reaction happens, your treatment will be stopped and emergency treatment will be given, including use of epinephrine.

**Infusion-Associated Reactions (IARs).**IARs occurred during or within 24 hours after receiving AVLAYAH, including:

  • Chills

  • Swelling

  • Low blood pressure (dizziness or fainting)

  • Fast heartbeat

  • Hives

  • Wheezing

  • Fever

  • Flushing or reddening of the skin

  • Rash

  • Cough

  • Diarrhea

  • Abdominal pain

  • Vomiting

  • Headache

  • Irritability

  • Small bumps on the skin

If you have an IAR, your doctor may slow down, pause, adjust your dose, or stop the infusion depending on how serious the reaction is. You may also be given medicine before infusions to help prevent these reactions. Patients with heart or lung problems may be at higher risk of serious complications from these reactions and will be monitored closely.

Anemia (Low Red Blood Cell Count) occurred during AVLAYAH treatment and may require periodic laboratory tests for hemoglobin. Contact your healthcare provider if you experience any symptoms (e.g., fatigue, pale skin) suggestive of anemia.

**Membranous Nephropathy (Kidney disorder that affects the filters that help remove wastes and fluids from the kidney)**occurred in an AVLAYAH-treated patient. Your doctor will monitor your kidney function during treatment.

The most common side effects (in 20% or more of patients):

  • Infusion-associated reactions

  • Upper respiratory infections

  • Ear infection

  • Fever

  • Anemia (low red blood cell count)

  • Cough

  • Vomiting

  • Diarrhea

  • Rash

  • COVID-19

  • Runny or congested nose

  • Falls

  • Headache

  • Skin injuries

  • Hives

October 22, 2026

PDF Version

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that it will report financial results and business highlights for the third quarter ended September 30, 2026, on Tuesday, November 3, 2026.

Denali’s management will host a conference call and webcast on Tuesday, November 3, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss third quarter 2026 financial results and provide a general business update.

The live webcast, along with a slide presentation, may be accessed through the Investors section of Denali’s website at www.denalitherapeutics.com or by clicking here. A replay of the webcast will be archived on Denali’s website for a limited time following the call.

About Denali Therapeutics

Denali Therapeutics Inc. is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier (BBB) using its proprietary TransportVehicle™ platform. With the first FDA-approved biologic specifically designed to cross the BBB, a clinically validated delivery platform and a growing portfolio of therapeutic candidates across all stages of development, Denali is advancing toward its goal of delivering effective medicines to transform life for people with neurodegenerative diseases, lysosomal storage disorders and other serious diseases. For more information, please visit www.denalitherapeutics.com.

Investor Contact: Laura Hansen[email protected]

Primary Logo

Source: Denali Therapeutics Inc.

Prompts

Denali Therapeutics Inc. (ticker DNLI), listed in United States.

ETFs Holding Denali Therapeutics Inc.

ETF Weight in ETF Shares Market value As of
TMED 1.22% 10,962 $ 281.943K Jun 30, 2026
TCAF 0.30% 1,787,595 $ 32.32M Nov 17, 2026
FDG 0.28% 49,525 $ 1.177M Aug 31, 2026
FTKI 0.24% 3,324 $ 60.098K Nov 16, 2026
TMSL 0.18% 194,297 $ 4.997M Jun 30, 2026
TCAL 0.13% 23,457 $ 424.103K Nov 17, 2026
RESM 0.12% 173 $ 4,449.56 Jun 30, 2026
FSEV 0.11% 295 $ 7,587.40 Jun 30, 2026
FSEG 0.07% 152 $ 3,909.44 Jun 30, 2026
VFMO 0.07% 52,680 $ 1.252M Aug 31, 2026
DFAS 0.06% 1,133,019 $ 21.403M Nov 12, 2026
FFF 0.06% 180 $ 3,720.60 Sep 30, 2026
FESM 0.04% 93,787 $ 2.412M Jun 30, 2026
MSSM 0.02% 6,500 $ 154.44K Aug 31, 2026
DXUV 0.01% 41,581 $ 785.465K Nov 12, 2026
DFAC 0.01% 464,478 $ 8.774M Nov 12, 2026
DCOR 0.01% 133,489 $ 2.522M Nov 12, 2026
DFAU 0.00% 33,880 $ 639.993K Nov 12, 2026
DFUS 0.00% 42,377 $ 800.502K Nov 12, 2026
AVUS 0.00% 10,276 $ 185.79K Nov 16, 2026
AVSU 0.00% 713 $ 12.891K Nov 16, 2026
AVIE 0.00% 20 $ 361.60 Nov 16, 2026